Stock Market & Financial Investment News

News Breaks January 3, 2013 07:52 EDT GEVA Synageva files to sell $80M in common stock Morgan Stanley and J.P. Morgan are acting as joint book-running managers in the offering, and Cowen and Company is acting as co-manager in the offering. News For GEVA From The Last 14 Days Check below for free stories on GEVA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 20, 2013 07:14 EDT GEVA Synageva says FDA grants 'Breakthrough Therapy' designation to sebelipase alfa Subscribe for More Information May 16, 2013 08:28 EDT GEVA Synageva has a conference call hosted by JPMorgan Subscribe for More Information May 10, 2013 08:05 EDT GEVA Synageva downgraded to Neutral from Overweight at JPMorgan JPMorgan downgraded Synageva citing concerns that the enrollment could be challenging for the sebelipase alfa Phase 3 trial. The firm lowered its price target for shares to $50 from $57. May 9, 2013 07:15 EDT GEVA Synageva's sebelipase alfa shows sustained effects and treatment tolerance Subscribe for More Information May 7, 2013 16:23 EDT GEVA Synageva to initiate natural history study of SBC-103 by mid-year Subscribe for More Information 16:21 EDT GEVA Synageva reaffirms FY13 net operating loss view ($97M)-($87M) Subscribe for More Information 16:20 EDT GEVA Synageva reports Q1 EPS (54c), consensus (70c) Reports Q1 revenue $5.12M, consensus $2.56M. Sign up for a free trial to see the rest of the stories you've been missing.